Table 1 Patient characteristics at baseline
From: Real-world data of anamorelin in advanced gastrointestinal cancer patients with cancer cachexia
ANAM 100 mg (n = 74) | |
|---|---|
Sex, no. (%) | |
Male | 49 (66.2) |
Female | 25 (33.8) |
Age: Median [range], year | 67.1 [36–83] |
Weight Median [range], kg | 51.2 [30.7–75.6] |
BMI: median [range], kg/m2 | 19.2 [13.1–28.2] |
ECOG PS, no. (%) | |
0 | 10 (13.5) |
1 | 44 (59.5) |
≥ 2 | 20 (27.0) |
Body weight loss, no. (%) | |
5–10% | 45 (60.8) |
> 10% | 29 (39.2) |
Albumin (g/dL), no. (%) | |
≥ 3.2 | 54 (73.0) |
< 3.2 | 27 (36.5) |
CRP (mg/dL), no. (%) | |
≥ 0.5 | 32 (43.2) |
> 0.5 | 42 (56.8) |
Hemoglobin (g/dL), no. (%) | |
≥ 12.0 | 17 (23.0) |
< 12.0 | 57 (77.0) |
Tumor type, no. (%) | |
Colorectal | 27 (36.5) |
Gastric | 20 (27.0) |
Pancreatic | 27 (36.5) |
Disease status, no. (%) | |
Locally advanced unresectable | 13 (17.6) |
Metastatic | 36 (48.6) |
Recurrence after surgery | 25 (33.8) |
No. of previous treatment regimens, no. (%) | |
0 | 20 (27.0) |
1 | 22 (29.7) |
≥ 2 | 32 (43.2) |
History of Gastric surgery, no. (%) | |
Total gastrectomy | 5 (6.8) |
Distal gastrectomy | 6 (8.1) |
Pancreaticoduodenectomy | 3 (4.1) |